SAB Biotherapeutics (SABS) Q1 2026 Earnings
SABS·Reported May 12, 2026·Before market open
Diluted EPS came in at $-0.35 (+37.5% YoY), missed the $-0.20 consensus by $0.15.
Diluted EPS
$-0.35missed by $0.15
Consensus: $-0.20
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about SAB Biotherapeutics's Q1 2026 earnings report.
SAB Biotherapeutics (SABS) reported Q1 2026 earnings on May 12, 2026 before market open.
SAB Biotherapeutics reported diluted EPS of $-0.35 for Q1 2026.
EPS missed the consensus estimate of $-0.20 by $0.15.
Compared to the same quarter a year prior, diluted EPS grew 37.5% from $-0.56.
You can read the 10-Q periodic report (0001193125-26-218195) directly on SEC EDGAR. The filing index links above go to sec.gov.